Interleukin 10 (IL-10) is a potent inhibitor of proliferative T cell responses toward alloantigens, and suppresses the production of pro-inflammatory cytokines which are important in cellular activation and recruitment to sites of inflammation. Because of these properties, we hypothesized that high IL-10 production in patients prior to BMT may predict a better outcome. To investigate this, peripheral blood mononuclear cells (PBMNC) were obtained from 58 recipients (11 autologous, 25 related donor (RD), and 22 unrelated donor (URD)), prior to conditioning therapy. PBMNC were cultured for 24 h in the presence and absence of lipopolysaccharide (LPS) and culture supernatants were assayed for IL-10 using an ELISA method. Spontaneously produced and LPSstimulated IL-10 levels were correlated with the development of transplant-related complications (TRC) including grade II-IV acute GVHD, veno-occlusive disease, idiopathic pneumonia syndrome and multi-organ dysfunction syndrome, and with death before day 100. For the autologous group, there were no TRC and only one death prior to day 100; therefore, no statistical comparisons to IL-10 levels could be made. In the RD group, 36% developed one or more TRC and 24% died before day 100; however, there were no statistically significant associations between spontaneous or LPS-induced IL-10 levels. In URD patients 41% developed TRC and 55% died prior to day 100. In this group, higher levels of spontaneous IL-10 production were associated with a lower overall occurrence of TRC (P = 0.03) and early death (P = 0.04). Our data would indicate that higher levels of IL-10 production prior to URD BMT may predict fewer TRC, as well as early deaths. The hypothesis that high IL-10 production prior to BMT may decrease complications following URD BMT warrants further testing.
Hematopoietic stem cell transplantation (HSCT) is associated with a variety of complications that can result in progressive functional deterioration of many organ systems and subsequently death. 1 The major non-infectious transplant-related complications (TRC) seen in the first 100 days following HSCT include veno-occlusive disease of the liver (VOD), graft-versus-host disease (GVHD), idiopathic pneumonia syndrome (IPS), and multi-organ dysfunction syndrome (MODS). Overall, 10-40% of transplanted patients will succumb to one of these TRC. [2] [3] [4] [5] [6] [7] The reasons why only some patients develop these complications is unknown. During HSCT, abnormalities of pro-inflammatory cytokine production have been linked to the development of TRC including GVHD, [8] [9] [10] [11] MODS, and IPS. 12 Recently, interest has focused on cytokines which may have immunomodulatory and inhibitory effects. IL-10 was initially described as cytokine synthesis inhibitory factor, a product of Th2 clones, which inhibited Th1 cytokine production and function. [13] [14] [15] It is produced by a variety of cells including activated T lymphocytes, monocytes and B cells. 16, 17 IL-10 strongly inhibits the antigen-specific proliferative responses of T cells. 15, 18 It suppresses the production of various pro-inflammatory cytokines such as IL-1␣, IL-1␤, IL-6, and TNF-␣, which play a role in the activation of granulocytes, monocytes, macrophages, natural killer cells, T cells, and B cells and their recruitment to sites of inflammation. [19] [20] [21] [22] Due to the suppressive properties of IL-10 on the inflammatory response, we hypothesized that high IL-10 production prior to HSCT may predict improved HSCT outcomes and a lower incidence of TRC.
Patients and methods

Patients
Between August 1994 and August 1996, 58 patients undergoing either autologous (n = 11), related donor (RD) (n = 25) or unrelated donor (URD) (n = 22) HSCT at the University of Minnesota had peripheral blood collected to establish mononuclear cell cultures. Patient characteristics are presented in Table 1 . All specimens were collected prior to the start of the preparative therapy or other intervention. All patients or their guardians signed consents which had been approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota.
Pretransplant conditioning therapy
Patients underwent conditioning therapy based upon their underlying disease. For 75% of allogeneic patients with malignancies this consisted of cyclophosphamide and total body irradiation (TBI). Additional patients received either cyclophosphamide, etoposide and TBI, or busulfan and cyclophosphamide. Patients with non-malignant conditions received either busulfan and cyclophosphamide, or cyclophosphamide and total lymphoid irradiation or TBI.
Supportive care
Patients were hospitalized in private rooms with highefficiency particulate air (HEPA) filtration. Antibiotic prophylaxis with trimethoprim-sulfamethoxazole was administered before the development of fever. At the onset of fever, patients received empiric broad-spectrum anti-bacterial and anti-fungal agents. Those patients seronegative for cytomegalovirus (CMV) received blood products from seronegative donors, or blood products were filtered to remove contaminating leukocytes. Patients seropositive for CMV or herpes simplex virus received acyclovir prophylaxis.
Graft-versus-host disease
GVHD was diagnosed and graded by standard criteria. 23, 24 GVHD prophylaxis consisted of cyclosporin (CsA) and 7 (n = 31), T cell depletion by counterflow elutriation 25 (n = 9, URD only), umbilical cord blood with methylprednisolone and CsA (n = 4, one related, three unrelated), and single drug regimens in three related donor patients with either CsA, methotrexate, or methylprednisolone.
Transplant-related complications
The occurrence of TRC including VOD, IPS, and MODS were determined based upon review of transplant complication reports generated for each patient from the BMT database at the University of Minnesota. IPS was defined as interstitial infiltrates on chest radiograph with no infectious etiology determined by bronchoscopy or open lung biopsy (or at autopsy); VOD was defined by standard clinical criteria. 4 Patients were classified as having MODS if they had evidence of hepatic (bilirubin Ͼ2× normal), renal (serum creatinine Ͼ2× normal, and pulmonary (hypoxia on room air) dysfunction at minimum, although most with MODS had severe organ dysfunction requiring mechanical ventilation and/or renal dialysis.
Peripheral blood mononuclear cell cultures and IL-10 assay
Peripheral blood was obtained by venipuncture or from a central venous catheter. After Ficoll-Hypaque centrifug-ation, mononuclear cells were washed twice in PBS buffer and placed in Yssels medium containing 1% human AB serum (Gemini Bio-Products, Calabasas, CA, USA) supplemented with 10% fetal calf serum. After Ficoll-Hypaque separation, the mononuclear cell concentration was Ͼ80%, and monocytes comprised 2-10% as determined by flow cytometric analysis. To analyze spontaneous and lipopolysaccharide (LPS)-induced (1 g/ml, Difco, Detroit, MI, USA) cytokine production, 1 × 10 6 cells/ml were cultured in duplicate for 24 h at 37°C in 24-well plates (Nunc, Wiesbaden, Germany) in a 5% CO 2 incubator with a humidified atmosphere. After 24 h, supernatants of individual patient cultures were collected and frozen at −20°C.
IL-10 was analyzed in duplicate samples from supernatants of PBMNC cultures using an ELISA method. Briefly, two different highly specific monoclonal antibodies for human IL-10 (coating mAb Jess-9D7; detecting mAb Jess-12G8.1) were used for capture and detection of IL-10. Detection was performed by a peroxidase-coated goat-anti- rat IgG antibody (J4-HRP, all antibodies provided by DNAX, Palo Alto, CA, USA). The sensitivity of the IL-10 assay was 20 pg/ml. A standard curve was constructed using recombinant human IL-10 protein with protein amounts Ͻ20 pg/ml which were readily detected by the ELISA. Values were calculated from this standard curve using a computer generated program.
Statistical methods
Transplant-related complications and early deaths were examined in a yes/no fashion among related donor and unrelated donor transplant patients. The Wilcoxon ranksum test was used to compare the distributions of spontaneous and LPS-induced IL-10 levels among patients who developed TRC (VOD, GVHD, MODS, IPS) or died before day 100 with those patients who did not develop complications or early death. P values were not adjusted for multiple comparisons. Table 1 details the characteristics of the patient cohort. The median age of the patients was 36 years with a range of 3 to 60 years. The majority of patients (76%) were у18 years. Transplants were performed for malignant disorders in 52 patients (90%) and for non-malignant conditions in six patients (10%). Donor source was bone marrow in 79%, peripheral blood stem cells (PBSC) in 14% and cord blood in 7%. Ninety-two percent of RD patients were HLA-identical, as were 46% of URD. The additional URD were HLAdisparate at minor antigens in 32% or A or B major mismatches in 22%.
Results
Patient characteristics
Relationship between IL-10 levels and post-transplant morbidity and mortality: autologous donors
For the 11 patients in the autologous transplant group, no TRC developed and only one patient died prior to day 100. Therefore, no statistical comparisons to IL-10 levels could be made and no further analysis was performed.
Relationship between IL-10 levels and post-transplant morbidity and mortality: related donors
IL-10 levels for those with and without TRC, GVHD, and early death for related and URD groups are listed in Table 2 . In the group of 25 patients undergoing related donor transplantation, there were nine (36%) patients who developed one or more TRC (Figure 1 ). These included: seven (28%) grade II-IV acute GVHD, two (8%) VOD, four (16%) MODS, five (20%) IPS. Six patients (24%) died prior to day 100. When IL-10 levels were compared between those patients who developed TRC or died prior to day 100 and those who did not experience TRC, there were no statistically significant differences in spontaneous or LPS-induced IL-10 production (median spontaneous IL-10 levels were 48 pg/ml vs 15 pg/ml, P = NS; LPS induced, 674 vs 278, P = NS; Figure 2 ). Similarly, for the occurrence of early death there was no statistically significant difference in median IL-10 levels between patients who died before day 100 and those who did not in endogenous or LPS-stimulated conditions ( Figure 3 ).
Relationship between IL-10 levels and post-transplant morbidity and mortality: unrelated donors
The same analysis was completed in the 22 URD patients (Table 2 ). Of those, nine patients (41%) developed one or more TRC (Figure 1 ). The TRC in this group consisted of grade II-IV acute GVHD in seven (32%), VOD in three (14%), IPS in five (23%), and MODS in seven (32%). Twelve (55%) of these patients died prior to day 100. However, the spontaneous production of IL-10 in URD patients who developed a TRC was significantly lower than in patients who did not develop a TRC (13 pg/ml vs 53 pg/ml, P = 0.03; Figure 4) . A similar trend was noted in the LPSinduced IL-10 production (28 pg/ml vs 421 pg/ml), but this did not reach statistical significance (Figure 4) . Similarly, those patients who died prior to day 100 were found to have lower levels of spontaneous IL-10 production than those who did not (31 pg/ml vs 189 pg/ml, P = 0.04; Figure 5 ). This same trend was noted for the LPS-stimulated condition but did not reach statistical significance (51 pg/ml vs 532 pg/ml; Figure 5 ). Patient numbers may have been too small to identify any individual TRC which may have been prevented by higher IL-10 production for either RD or URD transplants.
Discussion
We have investigated whether higher levels of IL-10 present pretransplant might protect patients from the development of significant TRC such as acute GVHD, MODS, IPS, VOD or death in the first 100 days post-transplant. These data support the hypothesis that high endogenous production of IL-10 can decrease the incidence of these significant TRC and early death. However, possibly due to the relatively small sample size from each donor source, we could only confirm this finding in the URD transplant setting. We were not able to detect differences when each TRC was evaluated separately. The finding that increased endogenous production of IL-10 is associated with a lower incidence of TRC and early death in URD transplant patients is likely due to IL-10's inhibition of pro-inflammatory cytokine production and suppression of inflammatory cell recruitment to sites of injury. [19] [20] [21] [22] The half-life of IL-10 is Ͻ4 h, 26 and the protective effect is likely to be due to continued IL-10 production by mononuclear cells during the conditioning therapy which suppresses the inflammatory response induced by the radiation and chemotherapy. Furthermore, the presence of IL-10 from host cells during the initial stages of engraftment may suppress donor alloresponsiveness, but subsequent IL-10 production is likely from donor-derived cells. Our data would suggest that the protective effect of IL-10 on TRC and day 100 mortality may in large part be due to the initial host mononuclear cells' ability to produce IL-10 during the conditioning therapy. While we could not isolate a protective effect on the development of GVHD in this study, murine studies have determined that IL-10 released from donor T cells reduces GVHD-induced lethality and that low dose IL-10 infusions inhibit the induction of lethal GVHD. 27 In contrast, these same studies determined that high doses of IL-10 accelerated GVHD lethality mediated by either CD4 + or CD8 + T cells. Similar findings have been reported in one human study which found that high serum IL-10 levels following BMT were associated with fatal outcomes such as septic shock or GVHD. 28 However, in support of a potential protective effect from endogenous recipient production of IL-10 is a recently reported study of 144 HLA-identical sibling transplants which found that recipients with IL-10 gene polymorphisms, which result in lower endogenous IL-10 production, had significantly higher rates of grades III-IV acute GVHD. 29 Additional studies will be required to further investigate the potential protective role of endogenous IL-10 production in GVHD.
In the recipients of RD grafts, one might assume that the same protective effect on TRC and early death from higher IL-10 production should have been found as well. This pilot study included very small numbers of patients and, in the related donor group, fewer events occurred making it more difficult to detect an association. Data to support this assumption has been reported by Holler et al 30 who also found that increased spontaneous production of IL-10 prior to conditioning therapy protected allogeneic transplant patients from GVHD and mortality following transplantation. Despite these cumulative data, it is possible that there could be a difference in the quality of the immune response between RD and URD recipients, such that high IL-10 may negatively regulate the immune response in one setting but not the other. For example, it has been demonstrated previously that human CD8
+ T cells can be inhibited or stimulated by IL-10 dependent upon the context of antigenic stimulation. 31 Our data did not show that IL-10 levels from LPS-stimulated monocytes correlated with TRC or early death. Higher endogenous levels may indicate that cells are already stimulated in vivo due, for example, to circulating endotoxin, and therefore that endogenous levels are more important. High endogenous production of IL-10 has been found to be associated with skin 32 and cardiac allograft acceptance 33, 34 and with the induction of neonatal tolerance. 35 Importantly, high endogenous levels of IL-10 mRNA were detected in PBMC obtained from long-term SCID patients who received successful fetal liver or haploidentical BM transplants and were tolerant to host alloantigens in vivo. 36, 37 These findings raise the question as to whether the administration of low doses of IL-10 pretransplant could protect against the development of TRC including GVHD. The quantity of IL-10 available locally or systemically following BMT may be important in determining whether IL-10 will act as an immunosuppressive or immunostimulatory cytokine for alloresponses. Larger studies will be needed in order to confirm our findings.
